. Author manuscript; available in PMC: 2011 Apr 14.

Published in final edited form as: N Engl J Med. 2010 Oct 14;363(16):1499–1509. doi: 10.1056/NEJMoa0906626

Table 2.

Mutations Causing Nevirapine Resistance at Baseline in Trial 1.^*

Mutation	Nevirapine (N = 121)	Ritonavir-Boosted Lopinavir (N = 120)	Total (N = 241)
	number (percent)
Present
No	105 (88)	101 (85)	206 (86)
Yes	15 (13)	18 (15)	33 (14)
K103N	11 (9)	12 (10)	23 (10)
K103N, G190A	0	1 (1)	1 (0.4)
K103N, Y181C	1 (1)	2 (2)	3 (1)
K103N, V108I, G190A	0	1 (1)	1 (0.4)
G190A	1 (1)	0	1 (0.4)
V108I	0	1 (1)	1 (0.4)
Y181C	1 (1)	1 (1)	2 (1)
Y181I	1 (1)	0	1 (0.4)
Test result not available	1	1	2

Percentages shown are for participants with available test results.